Innovent and UNION Therapeutics Enter into Strategic Collaboration and License Agreement for Orismilast, a Next-generation PDE4 Inhibitor for Inflammatory Dermatology Conditions
SAN FRANCISCO and SUZHOU, China and HELLERUP, Denmark, Sept. 28, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, and UNION therapeutics A/S (UNION), a privately-held, multi-asset, clinical stage, pharmaceutical company focused on immunology and infectious...
Brii Bio Appoints Coy Stout as Senior Vice President and Head of U.S. Market Access and Patient Advocacy
DURHAM, N.C. and BEIJING, Sept. 28, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, today announced the appointment of Coy Stout as Senior Vice President and Head of U.S. Market Access and Patient Advocacy. Mr. Stout brings...
LifeWave Notches Prestigious Inc. 5000 Distinction for the 4th time with Fast Growth and Bold Product Innovation
TOKYO, Sept. 28, 2021 /PRNewswire/ -- Cutting-edge health technology company, LifeWave, has solidified its place as one of America's fastest growing privately held companies by again making the Inc. 5000 list for 2021. Released in mid-August, the publication asserts that "brains, bravery, and optimism propelled these businesses to our annual fast-growth list,...
Neurophth Announces the Completion of GMP Manufacturing Facility for Gene Therapy Products According to International Standards
WUHAN, China and SAN DIEGO, Sept. 27, 2021 /PRNewswire/ -- Neurophth Biotechnology Ltd., a fully-integrated genomic medicines company seeking to improve lives through the curative potential of gene therapies, announced the opening of its state-of-the-art manufacturing facility at the Phase II Suzhou Biomedical Industrial Park (BioBAY) in Suzhou, China. ...
Ortho Customers Rank Company No. 1 in Service and Support for Sixth Consecutive Year
Company receives top customer rating across six categories in the 2021 IMV ServiceTrak™ Awards RARITAN, N.J., Sept. 27, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) today announced that for the sixth consecutive year its Ortho Care™ Service and Support program was ranked No. 1 in the diagnostics industry for the 2021...
Harbour BioMed Announces Dosing of First Patient of Batoclimab Phase III Trial in Patients with Generalized Myasthenia Gravis
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Sept. 27, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced that, the clinical trial of its anti-FcRn antibody, batoclimab (HBM9161), has completed the first dosing of first patient in registrational phase III trial for the treatment of generalized myasthenia gravis (gMG). This clinical study...
Immunoforge Inc. receives U.S. FDA ODD for Treatment of Polymyositis
SEOUL, South Korea, Sept. 27, 2021 /PRNewswire/ -- Immunoforge (Co-CEOs Sung-min Ahn, Kiho Chang), a company specializing in developing new drugs for rare musculoskeletal diseases, has reported that their new drug candidate PF1801 has received Orphan Drug Designation (ODD) from the U.S. FDA for the treatment of Polymyositis. The FDA designates solutions for rare incurable diseases or life-threatening diseases...
Bo’ao Winhealth Rare Disease Medical Center and Ali Health Jointly Launched the “Global Drug Information Platform for Rare Diseases”
BEJING, Sept. 27, 2021 /PRNewswire/ -- On September 25, 2021 in Beijing, China, the "Global Drug Information Platform for Rare Diseases" was successfully kicked off at Ali Center in Beijing. Jointly built by Bo'ao Winhealth Rare Disease Medical Center and Ali Health, the Platform aims at addressing the challenges of unavailability and unaffordability of the overseas innovative therapies facing...
CGBIO to introduce AI-empowered robotic intervention device, with clinical trials
CGBIO, NDR Medical Technology, forge a partnership in a move to introduce puncture robot technology and collaborate in clinical studies. CGBIO expects this partnership to gain its stronger competitiveness in the global digital healthcare market beyond the presence as a pioneer of AI based healthcare technology. SEOUL, South Korea, Sept. 27, 2021 /PRNewswire/ -- CGBIO Inc., a...
JW Therapeutics Announces IND Approval for the Clinical Trial of JWCAR129
SHANGHAI, Sept. 27, 2021 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, today announced that it has received the Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA) of China for a clinical trial of BCMA-targeted Chimeric Antigen Receptor (CAR) T cell JWCAR129 in treating relapsed...
